Philipp Alberts (Ph.D)

Philipp Alberts (Ph.D) has extensive work experience in the field of biotechnology and scientific research. Philipp currently holds the position of Director of Translational Research at Scenic Biotech, where they started in March 2023. Prior to this, they worked as a Senior Principal Scientist at eTherapeutics from March 2022 to January 2023.

Before joining eTherapeutics, Philipp Alberts served as a Group Leader at Galapagos from July 2020 to January 2022. Prior to that, they held various roles at Northern Biologics, starting as a Senior Scientist in December 2014 and later becoming a Principal Scientist in October 2016. In these positions, they led preclinical antibody development projects with a focus on immune-oncology and fibrosis. Philipp guided projects through IND enabling studies and was responsible for candidate selection, preclinical pharmacology, and the development of target engagement and proof-of-concept studies.

Earlier in their career, Philipp Alberts worked as a Team Leader for Validation Biological Therapeutics - Oncology at the University Health Network from May 2012 to November 2014. Philipp was involved in biological validation of genes related to cancer vulnerabilities and developed assays to screen and validate synthetic antibodies.

Philipp also gained research experience as a Research Fellow at The Hospital for Sick Children from March 2009 to April 2012, and as an EMBO postdoctoral fellow at Yale University from January 2005 to December 2008.

Philipp Alberts completed their PhD at Institut Curie in 1999, focusing on an undisclosed subject. Philipp started their academic journey as a student at the University of Cologne in 1994.

Philipp Alberts obtained their Ph.D in Biology from the University of Cologne. Philipp pursued their doctoral studies from 1994 to 2004 in the same field at the mentioned institution.